Clinical Trial26 May 2026, 06:31 pm
Sun Pharma: UNLOXCYT™ Data Presented at ASCO 2026
AI Summary
Sun Pharmaceutical Industries will present updated results from the pivotal CK-301-101 trial of UNLOXCYT™ (cosibelimab-ipdl) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The data shows a 50% objective response rate in patients with locally advanced cutaneous squamous cell carcinoma (laCSCC), including 27% complete responses. The median duration of response was not yet reached after a median follow-up of 31 months. The safety profile was consistent with previous analyses.
Key Highlights
- Sun Pharma to present UNLOXCYT™ data at ASCO 2026 on May 31 in Chicago.
- Study shows 50% objective response rate in laCSCC patients treated with UNLOXCYT™.
- 27% of patients experienced complete responses with durable results.
- The median duration of response was not reached after 31 months follow-up.
- UNLOXCYT™ demonstrated a manageable safety profile in the study.